A Tribute to Dr. John Sarno

Steven Peskin MD

At age 89, Dr. John Sarno has retired from his clinical practice at the Howard A. Rusk Institute of Rehabilitation Medicine at New York University School of Medicine where he is a professor of rehabilitation medicine. I consider John a friend, a thought-creator in the field of mind body medicine, and someone to whom I owe a profound debt of gratitude in that my wife, Suzanne, was cured of seven years of debilitating back pain by embracing the etiology of her pain as psychologically based.

Dr. Sarno developed his theory —  Tension Myositis Syndrome — after more than a decade in practice as a physical medicine and rehabilitation physician in academic medicine. He observed patterns of behavior and personality traits that were shared by large numbers of patients with back pain and other pain syndromes.  

 Dr. Sarno’s controversial approach to back pain, other types of chronic musculoskeletal pain — neck, shoulder, infrascapular — and other pain syndromes including migraine and carpal tunnel syndrome, is a two-part lecture to educate patients on the underlying psychological causes or triggers leading to mild oxygen deprivation to certain muscle groups. His mantra is, “The pain is real, but the cause of your pain is not.”

John has successfully treated over 12,000 patients and has helped countless others who have read one of his four books —"The Mind-Body Connection" — or who have been treated by a handful of Sarno disciples. A criticism of Sarno’s self-reported success rate of greater than 95% is selection bias. It is true that Dr. Sarno would not take as a patient someone who was unwilling to accept that his/her pain might be psychologically based. That said, I argue that John was ahead of his time — utilizing individualized medicine.

Thank you, John.  

Steven R. Peskin, MD, MBA, FACP, is associate clinical professor of medicine at the University of Medicine and Dentistry of New Jersey — Robert Wood Johnson Medical School.

APRIL 2012


Thomas J. Foels, MD 

Reform Forces Health Insurers to Reinvent Themselves

To paraphrase Mark Twain, the death of the health insurance industry has been greatly exaggerated. Plans simply have to develop new business models.


Charles Kennedy 

Regina E. Herzlinger, PhD 

James C. Robinson, PhD, MPH 

A Conversation with James C. Robinson, PhD, MPH: Waiting for Economic Pressure to Force Our Hand

The UC–Berkeley health care economist says the cost-control and performance-improvement methods we’ve been developing for years can work, but implementing them on a wide scale may come as a last resort


 

Payers, Providers Weigh Value of Some Costly Biologics

Provenge is just one example of an expensive biotechnology drug whose survival analyses leave much to be desired


Elizabeth Malko, MD 

Diagnosis of Sleep Apnea Moves From Lab to Home

Treating sleep apnea greatly reduces global costs, but compliance remains a concern

Departments

Legislation & Regulation  

Clarifying Benefit Packages Takes Time, Insurers Insist

Health plan officials are not doing handstands over the federal government’s extension of a deadline to disclose benefits to members in a readable form

Medication Management  

New Diabetes Medications Drive Up Costs And Stymie Formulary Design

Insurers feel pressure to incorporate new agents into their drug benefit, but evidence of effectiveness is questionable

Evidence Review  

Trisomy 21 DNA Test (MaterniT21) for Detecting Down Syndrome in the First Trimester

A summary of ECRI Institute’s Health Technology Forecast Report

Snapshot  

Obesity’s Link to Certain Cancers Puts Wellness Programs on Trial

Employers and the federal government like these programs, but some question their cost-effectiveness

Tomorrow’s Medicine  

Targeting a Cystic Fibrosis Mutation Opens Door for Personalized Treatment

There are many genetic mutations attributable to the condition, but Kalydeco can significantly help a specific subpopulation of patients